<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575898</url>
  </required_header>
  <id_info>
    <org_study_id>D15113</org_study_id>
    <nct_id>NCT02575898</nct_id>
  </id_info>
  <brief_title>Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study</brief_title>
  <official_title>Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the feasibility of a creative writing intervention in an advanced cancer
      population. Given it is a relatively simple intervention delivered by a non-clinician, the
      investigators are interested in better understanding its pattern of effect on patient
      psychological adjustment. The investigators aim to assess its feasibility in this study in
      order to inform a future larger study that will utilize a control arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be recruited within 3 months of presenting with a new GI or lung primary,
      non-curable malignancy. After consent, the participants will meet with the staff writer, who
      is already part of the creative arts program, to determine the methods, themes and modalities
      of creative writing to pursue. These choices will be revisited each session, as patients move
      from one theme to another, and some patients may consistently choose a given modality such as
      letters, while others will choose variety.

      Participants will meet with the staff writer one-on-one by scheduled appointment in the
      outpatient or inpatient setting at a minimum of once per month throughout a 6 month time
      period after enrollment. This appointment is preferred to be in person, but due to the rural
      setting may be conducted by telephone if needed. There will not be a protocol regarding the
      length of and number of visits during the 6 month study period, but these quantities will be
      recorded to use for analysis of effectiveness of the intervention.

      Writing modality choices will include private thoughts and feelings in a journal, poetry,
      letters to oneself or loved ones and narrative writing about significant life events. All
      interventions will focus on a written product for the participant to have and potentially
      share with caregivers if they desire.

      Every 3 months patients will be asked to complete the following series of questionnaires:
      ECOG PS, PGAC3, HADS4, DT5, CSE6, CD-RISC-107, PTGI-SF8, FACIT-Sp-Ex9, ESAS11 and PA10.

      Patients will be followed for 9 months after enrollment or until death (whichever is
      soonest). If a patient decides to discontinue the creative writing intervention before 6
      months, the reason will be recorded and they will continue in the study for 9 months or until
      death completing the questionnaires.

      Anyone completing the first intervention with the creative writer will be evaluable for the
      feasibility outcome. If the investigators see 50% of patients completing 3 months of the
      creative writing intervention then this would indicate the intervention should be examined in
      a larger pilot study. In addition, the investigators will carefully record accrual rate with
      associated reasons for declining and number of patients able to complete the full planned
      intervention with the creative writing. In planning for a larger pilot study next and given
      the survey burden is high in this study, the investigators will plan to use a subset analysis
      in order to see which factors were significantly affected by the creative arts intervention
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 14, 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of a creative writing intervention in an advanced cancer population</measure>
    <time_frame>29 months</time_frame>
    <description>Anyone completing the first intervention with the creative writer will be evaluable for the feasibility outcome. If the investigators see 50% of patients completing 3 months of the creative writing intervention then this would indicate the intervention should be examined in a larger pilot study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Primary Malignant Neoplasm of Lung</condition>
  <condition>Primary Malignant Neoplasm of Gastrointestinal Tract</condition>
  <arm_group>
    <arm_group_label>One</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Creative writing and questionnaires interventions:
First Session, Second Session, Third through Sixth Sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>First Session</intervention_name>
    <description>Creative Practice and Positive Re-enforcement</description>
    <arm_group_label>One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Second Session</intervention_name>
    <description>Disease Related</description>
    <arm_group_label>One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Third through Sixth Sessions</intervention_name>
    <description>Life Review and Legacy</description>
    <arm_group_label>One</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant must plan to receive follow up care at Dartmouth-Hitchcock.

          2. Participant must have a lung or GI primary cancer diagnosed in the last 3 months.

          3. Participant must have non-curable cancer as judged by the primary oncologist.

          4. Participant must be comfortable conversing in English (reading and writing in English
             is not required).

          5. Participant must be cognitively intact as judged by their responsible clinician.

          6. Participant must have access to a working telephone and be willing and available to
             participate by this modality as needed.

          7. Participants may be on anti-depressants and/or anxiolytics as long as the dosing has
             remained stable over the preceding 2 weeks.

        Exclusion Criteria:

          1. Participant is expected to die in 6 months or less as judged by the responsible
             clinician.

          2. Participant must not have already worked with the staff writer at Dartmouth Hitchcock
             prior to enrollment in this study.

          3. Participant with an activated durable power of attorney for health care or cognitive
             impairment that interferes with ability to understand prognosis as determined by the
             primary oncologist.

          4. Participant must not have uncontrolled physical symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max Vergo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678.</citation>
    <PMID>20818875</PMID>
  </reference>
  <reference>
    <citation>Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, Lennes IT, Dahlin CM, Pirl WF. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011 Jun 10;29(17):2319-26. doi: 10.1200/JCO.2010.32.4459. Epub 2011 May 9.</citation>
    <PMID>21555700</PMID>
  </reference>
  <reference>
    <citation>Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Heist RS, Gallagher ER, Temel JS. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 2012 Feb 1;30(4):394-400. doi: 10.1200/JCO.2011.35.7996. Epub 2011 Dec 27.</citation>
    <PMID>22203758</PMID>
  </reference>
  <reference>
    <citation>Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, Dionne-Odom JN, Frost J, Dragnev KH, Hegel MT, Azuero A, Ahles TA. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. J Clin Oncol. 2015 May 1;33(13):1438-45. doi: 10.1200/JCO.2014.58.6362. Epub 2015 Mar 23.</citation>
    <PMID>25800768</PMID>
  </reference>
  <reference>
    <citation>Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA. 2009 Aug 19;302(7):741-9. doi: 10.1001/jama.2009.1198.</citation>
    <PMID>19690306</PMID>
  </reference>
  <reference>
    <citation>Dionne-Odom JN, Azuero A, Lyons KD, Hull JG, Tosteson T, Li Z, Li Z, Frost J, Dragnev KH, Akyar I, Hegel MT, Bakitas MA. Benefits of Early Versus Delayed Palliative Care to Informal Family Caregivers of Patients With Advanced Cancer: Outcomes From the ENABLE III Randomized Controlled Trial. J Clin Oncol. 2015 May 1;33(13):1446-52. doi: 10.1200/JCO.2014.58.7824. Epub 2015 Mar 23.</citation>
    <PMID>25800762</PMID>
  </reference>
  <reference>
    <citation>Bohlmeijer E, Smit F, Cuijpers P. Effects of reminiscence and life review on late-life depression: a meta-analysis. Int J Geriatr Psychiatry. 2003 Dec;18(12):1088-94.</citation>
    <PMID>14677140</PMID>
  </reference>
  <reference>
    <citation>Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol. 2005 Aug 20;23(24):5520-5.</citation>
    <PMID>16110012</PMID>
  </reference>
  <reference>
    <citation>Ando M, Tsuda A, Morita T. Life review interviews on the spiritual well-being of terminally ill cancer patients. Support Care Cancer. 2007 Feb;15(2):225-31. Epub 2006 Sep 12.</citation>
    <PMID>16967303</PMID>
  </reference>
  <reference>
    <citation>Steinhauser KE, Alexander SC, Byock IR, George LK, Olsen MK, Tulsky JA. Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial. J Palliat Med. 2008 Nov;11(9):1234-40. doi: 10.1089/jpm.2008.0078.</citation>
    <PMID>19021487</PMID>
  </reference>
  <reference>
    <citation>Crogan NL, Evans BC, Bendel R. Storytelling intervention for patients with cancer: part 2--pilot testing. Oncol Nurs Forum. 2008 Mar;35(2):265-72. doi: 10.1188/08.ONF.265-272.</citation>
    <PMID>18321839</PMID>
  </reference>
  <reference>
    <citation>Chochinov HM, Kristjanson LJ, Breitbart W, McClement S, Hack TF, Hassard T, Harlos M. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol. 2011 Aug;12(8):753-62. doi: 10.1016/S1470-2045(11)70153-X. Epub 2011 Jul 6.</citation>
    <PMID>21741309</PMID>
  </reference>
  <reference>
    <citation>Puetz TW, Morley CA, Herring MP. Effects of creative arts therapies on psychological symptoms and quality of life in patients with cancer. JAMA Intern Med. 2013 Jun 10;173(11):960-9. doi: 10.1001/jamainternmed.2013.836. Review.</citation>
    <PMID>23699646</PMID>
  </reference>
  <reference>
    <citation>Korte J, Bohlmeijer ET, Cappeliez P, Smit F, Westerhof GJ. Life review therapy for older adults with moderate depressive symptomatology: a pragmatic randomized controlled trial. Psychol Med. 2012 Jun;42(6):1163-73. doi: 10.1017/S0033291711002042.</citation>
    <PMID>21995889</PMID>
  </reference>
  <reference>
    <citation>Juli√£o M, Oliveira F, Nunes B, Vaz Carneiro A, Barbosa A. Efficacy of dignity therapy on depression and anxiety in Portuguese terminally ill patients: a phase II randomized controlled trial. J Palliat Med. 2014 Jun;17(6):688-95. doi: 10.1089/jpm.2013.0567. Epub 2014 Apr 15.</citation>
    <PMID>24735024</PMID>
  </reference>
  <reference>
    <citation>Tegner I, Fox J, Philipp R, et al. Evaluating the use of poetry to improve well-being and emotional resilience in cancer patients. J Poetry Ther 2009; 22: 121-131.</citation>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Maxwell. T. Vergo</investigator_full_name>
    <investigator_title>Staff Physician, Palliative Care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

